Hemostasis abnormalities in cirrhosis

Current Opinion in Hematology

Volumn 22, Issue 5, 2015, Pages 406-412

  Tripodi, Armando ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cirrhosis; Factor VIII; Hemorrhage; Protein C; Thrombin generation; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; ELTROMBOPAG; FIBRIN; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN; PROCOAGULANT; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; ENDOGENOUS THROMBIN POTENTIAL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM; COMPLICATION; HEMORRHAGE; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD COAGULATION; FIBRINOLYSIS; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER CIRRHOSIS; THROMBOCYTOPENIA;

EID: 84942789718     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000164     Document Type: Review

References (53)

1. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008; 15: 473-480.
2. Violi F, Leo R, Vezza E, et al. Bleeding time in patients with cirrhosis: Relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994; 20: 531-536.
3. Boberg KM, Brosstad F, Egeland T, et al. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost 1999; 81: 378-381.
4. Mannucci PM. Desmopressin: An historical introduction. Haemophilia 2008; (Suppl 1) : 1-4.
5. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986; 67: 1148-1153.
6. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J 1985; 291: 1377-1381.
7. Cattaneo M, Tenconi PM, Alberca I, et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990; 64: 358-360.
8. de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, doubleblind study. New Italian Endoscopic Club. Hepatology 1993; 18: 1102-1107.
9. Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003; 50: 14-20.
10. Arshad F, Stoof SC, Leebeek FW, et al. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis. Liver Int 2015; 35: 1809-1815.
11. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
12. Tripodi A, Primignani M, Chantarangkul V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int 2013; 33: 362-367.
13. Afdhal NH, Giannini EG, Tayyab G, et al., ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724.
14. Tripodi A, Primignani M. Nontransfusional approach to increase platelet count in patients with cirrhosis and thrombocytopenia. Hepatology 2013; 58: 1177-1180.
15. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro-vs anticoagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-2111.
16. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11.
17. Tripodi A, Caldwell SH, Hoffman M, et al. The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26: 141-148.
18. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: Revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147: 77-82.
19. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-116.
20. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
21. Chantarangkul V, Clerici M, Bressi A, et al. Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hypo-or hyper-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma. Haematologica 2003; 88: 547-554.
22. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558.
23. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology 2006; 44: 440-445.
24. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-1046.
25. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-136.
26. Bosch J, Thabut D, Bendtsen F, et al., European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology 2004; 127: 1123-1130.
27. Bosch J, Thabut D, Albillos A, et al., International StudyGroup on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology 2008; 47: 1604-1614.
28. Lodge JP, Jonas S, Jones RM, et al., rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-979.
29. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11: 895-900.
30. Tripodi A, Chantarangkul V, Primignani M, et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma. Considerations on the efficacy of treatment with fresh frozen plasma. Intern Emerg Med 2012; 7: 139-144.
31. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
32. Søgaard KK, Horváth-Puhó E, Grønbaek H, et al. Risk of venous thromboembolism in patients with liver disease: A nationwide population-based casecontrol study. Am J Gastroenterol 2009; 104: 96-101.
33. Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52: 355-361.
34. Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
35. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut 2005; 54: 691-697.
36. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89: 279-286.
37. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-348.
38. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008; 47: 1384-1393.
39. Tripodi A, Primignani M, Lemma L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59: 265-270.
40. Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with nonalcoholic fatty liver disease. J Hepatol 2014; 61: 148-154.
41. Intagliata NM, Henry ZH, Shah N, et al. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34: 26-32.
42. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260.
43. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772-777.
44. Hersch SL, Kunelis T, Francio RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor. Blood 1987; 69: 1315-1319.
45. Tran-Thang C, Fasel-Felley J, Pralong G, et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 651-653.
46. Marongiu F, Mamusa AM, Mameli C, et al. Alpha 2 antiplasmin and disseminated intravascular coagulation in liver cirrhosis. Thromb Res 1985; 37: 287-294.
47. Sinclair TS, Booth NA, Penman SM, et al. Protease inhibitors in liver disease. Scand J Gastroenterol 1988; 23: 620-624.
48. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-670.
49. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-Activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
50. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-237.
51. Martí-Carvajal AJ, Solà I, Martí-Carvajal PI. Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease. Cochrane Database Syst Rev 2012; 9: CD006007.
52. Rockey DC, Caldwell SH, Goodman ZD, et al., American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044.
53. Senzolo M, Riddell A, Tuddenham E, et al. Endogenous heparinoids contribute to coagulopathy in patients with liver disease. J Hepatol 2008; 48: 371-372.